FRLN - Freeline posts early data for gene therapy in Gaucher disease
2023-10-04 11:45:25 ET
More on Freeline
- Freeline Therapeutics Holdings plc (FRLN) Q2 2023 Earnings Call Transcript
- Freeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62M
- Seeking Alpha’s Quant Rating on Freeline Therapeutics
- Historical earnings data for Freeline Therapeutics
- Financial information for Freeline Therapeutics
For further details see:
Freeline posts early data for gene therapy in Gaucher disease